Orthocell Ltd (ASX:OCC, OTC:ORHHF) will release its quarterly results for the period ended March 31, 2026, on Monday, April 20, and host an investor webinar the same day.
The webinar will cover its quarterly results and provide an operational update, including progress on the US rollout of Remplir and its use in prostate cancer surgeries in Australia.
Orthocell chair John Van Der Wielen, CEO and managing director Paul Anderson, and CFO Jim Piper will present the briefing.
The webinar is scheduled for 9am AWST / 11am AEDST on Monday, 20 April 2026.
Register now: https://Orthocell Ltd/Webinar/March Quarter/Register
Commercial momentum
Orthocell is beginning to generate commercial momentum from its expansion into the US market, marking a key step in the company’s long-flagged shift towards broader sales growth.
After several years of product development, regulatory approvals and early offshore sales, Orthocell is now establishing a presence for its nerve repair device Remplir in the US, its largest potential market and one of its most competitive. Early signs of adoption across hospitals and surgeons, including repeat use, point to growing traction as the company scales the rollout.
The opportunity is drawing attention to a large-volume area of surgery that remains relatively underpenetrated by advanced repair devices, with Orthocell indicating that even modest gains in uptake could support meaningful revenue growth.